Table 4.
The results of the cost-benefit analysis for three COVID-19 vaccines.
| Costsa | No vaccination | Vaccination |
Net cost (saving) of no vaccination versus vaccination |
||||
|---|---|---|---|---|---|---|---|
| Moderna | Pfizer | AstraZeneca | Moderna | Pfizer | AstraZeneca | ||
| Direct cost | |||||||
| Vaccine | 0.0000 | 52.7244 | 30.8519 | 18.9079 | 52.7244 | 30.8519 | 18.9079 |
| COVID-19 medical cost | 172.9218 | 25.7249 | 25.7741 | 36.5047 | (147.1968) | (147.1477) | (136.4170) |
| Indirect cost related to activities for vaccine jab and medical needs | 248.6040 | 77.0265 | 75.2695 | 111.5270 | (171.5775) | (173.3345) | (137.0771) |
| Benefit-cost ratio | |||||||
| Payer's perspective (BCR1) | – | – | – | – | 2.79 | 4.77 | 7.21 |
| Societal perspective (BCR2) | – | – | – | – | 6.05 | 10.39 | 14.46 |
| Economic impacts | |||||||
| Due to productivity and education loss | – | – | – | – | (791.34) | (798.91) | (592.03) |
| Value of statistical life | – | – | – | – | (14418.71) | (14414.57) | (13283.61) |
| Benefit-cost ratio | |||||||
| In terms of productivity and education loss (BCR3) | – | – | – | – | 13.54 | 23.32 | 28.85 |
| In terms of value of statistical life (BCR4) | – | – | – | – | 175.84 | 300.30 | 442.79 |
a
Data presented in individual average.